Latigo Biotherapeutics (LTGO)
Develops non-opioid NaV1.8 inhibitors for acute and chronic pain.
Something off on this page? Send us feedback.
Develops oral small-molecule NaV1.8 inhibitors for acute and chronic pain, with LTG-001 in late-stage preparation and LTG-321 in proof-of-concept work. Has no approved products or product revenue and relies on outsourced trials and manufacturing.
Develops selective small-molecule NaV1.8 inhibitors designed to block peripheral pain transmission without opioid pathways. The clinical portfolio comprises LTG-001 for moderate-to-severe acute and postoperative pain and LTG-321 for chronic musculoskeletal pain; LTG-418 and other ion-channel modulators remain preclinical or in discovery. Development pairs internal discovery and translational tools with outsourced clinical trials and third-party manufacturing.
Operates as a single research-and-development segment, with no approved products, product revenue, or internal sales, marketing, and distribution capability. Early clinical studies occurred in New Zealand, while the commercial opportunity is initially framed around the U.S. and FDA approval. LTG-001 depends on a licensed intellectual-property agreement, and all manufacturing, storage, distribution, and quality testing are performed by third parties.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Not reported.
No dividends on record.
| Insiders | 17.39% | 10.46M shares | |
|---|---|---|---|
| 3 holders · as of Aug 17, 2026 | |||
| Strategic holders | 46.81% | 28.16M shares | |
| 4 holders · as of Aug 18, 2026 | |||
| Other | 35.80% | 21.53M shares | |
| remainder | |||
60.15M company shares as of Aug 21, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Westlake BioPartners Fund I, L.P.Strategic10 percent owner | 21.94% | 13.20M | filed Aug 11, 2026 |
James B. TananbaumInsider | 15.26% | 9.18M | filed Aug 17, 2026 |
5AM Ventures VI, L.P.Strategic10 percent owner | 12.18% | 7.33M | filed Aug 12, 2026 |
RA Capital Management, L.P.Institution | 8.80% | 5.30M | filed Aug 17, 2026 |
Deep Track Capital, LPStrategic | 7.39% | 4.45M | filed Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 10, 2026 | Foresite Capital Management V, LLC | 10 percent owner | +140,000 | $18.00 |
| Aug 10, 2026 | James B. Tananbaum | director, 10 percent owner: | +140,000 | $18.00 |
- Vertex Pharmaceuticals
Commercial NaV1.8 leader in non-opioid acute pain.
- Eli Lilly
Same-mechanism chronic-pain contender through STC-004.
- Merck
Developing a once-daily oral NaV1.8 inhibitor for pain.
- AbbVie
NaV1.7/NaV1.8 pain research and in-licensed NaV1.8 assets.
- Xenon Pharmaceuticals
Early clinical NaV1.7 and Kv7 alternatives for acute pain.
- Biohaven
Kv7 ion-channel platform with research-stage pain potential.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Latigo Biotherapeutics | $20.17 | −3.14% | $1.25B | — | — | — | — |
| Vertex Pharmaceuticals | $514.35 | −0.12% | $130.71B | 30.0 | 26.8 | 10.4 | +12.5% |
| Eli Lilly | $1,160.35 | −0.84% | $1.10T | 39.3 | 28.4 | 13.8 | +47.7% |
| Merck | $148.02 | −1.92% | $372.73B | 120.7 | 17.2 | 5.6 | +5.1% |
| AbbVie | $266.16 | +0.36% | $468.77B | 74.8 | 17.5 | 7.3 | +10.2% |
| Xenon Pharmaceuticals | $37.23 | −4.76% | $3.78B | — | — | — | — |
| Biohaven | $14.10 | −5.05% | $2.24B | — | — | — | — |
| Median | 57.0 | 22.1 | 8.8 | +11.3% |